Logo image of ARTL

ARTELO BIOSCIENCES INC (ARTL) Stock Fundamental Analysis

NASDAQ:ARTL - Nasdaq - US04301G5080 - Common Stock

1.2  +0.02 (+1.69%)

After market: 1.12 -0.08 (-6.67%)

Fundamental Rating

2

Taking everything into account, ARTL scores 2 out of 10 in our fundamental rating. ARTL was compared to 195 industry peers in the Pharmaceuticals industry. ARTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARTL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARTL had negative earnings in the past year.
In the past year ARTL has reported a negative cash flow from operations.
In the past 5 years ARTL always reported negative net income.
ARTL had a negative operating cash flow in each of the past 5 years.
ARTL Yearly Net Income VS EBIT VS OCF VS FCFARTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -127.82%, ARTL is doing worse than 83.33% of the companies in the same industry.
ARTL has a Return On Equity of -143.39%. This is in the lower half of the industry: ARTL underperforms 65.05% of its industry peers.
Industry RankSector Rank
ROA -127.82%
ROE -143.39%
ROIC N/A
ROA(3y)-59.81%
ROA(5y)-63.82%
ROE(3y)-64.26%
ROE(5y)-70.54%
ROIC(3y)N/A
ROIC(5y)N/A
ARTL Yearly ROA, ROE, ROICARTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K 1.5K

1.3 Margins

ARTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTL Yearly Profit, Operating, Gross MarginsARTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

ARTL has more shares outstanding than it did 1 year ago.
ARTL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ARTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARTL Yearly Shares OutstandingARTL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
ARTL Yearly Total Debt VS Total AssetsARTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -9.83, we must say that ARTL is in the distress zone and has some risk of bankruptcy.
ARTL's Altman-Z score of -9.83 is on the low side compared to the rest of the industry. ARTL is outperformed by 75.81% of its industry peers.
There is no outstanding debt for ARTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.83
ROIC/WACCN/A
WACCN/A
ARTL Yearly LT Debt VS Equity VS FCFARTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

ARTL has a Current Ratio of 7.15. This indicates that ARTL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARTL (7.15) is better than 75.27% of its industry peers.
A Quick Ratio of 7.15 indicates that ARTL has no problem at all paying its short term obligations.
The Quick ratio of ARTL (7.15) is better than 76.34% of its industry peers.
Industry RankSector Rank
Current Ratio 7.15
Quick Ratio 7.15
ARTL Yearly Current Assets VS Current LiabilitesARTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.31% over the past year.
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ARTL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.71% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.72%
EPS Next 2Y31.8%
EPS Next 3Y21.9%
EPS Next 5Y13.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ARTL Yearly Revenue VS EstimatesARTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ARTL Yearly EPS VS EstimatesARTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTL Price Earnings VS Forward Price EarningsARTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTL Per share dataARTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ARTL's earnings are expected to grow with 21.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.8%
EPS Next 3Y21.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARTL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARTELO BIOSCIENCES INC

NASDAQ:ARTL (1/22/2025, 8:05:30 PM)

After market: 1.12 -0.08 (-6.67%)

1.2

+0.02 (+1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners0.8%
Inst Owner Change0%
Ins Owners0.83%
Ins Owner Change0%
Market Cap3.88M
Analysts84
Price Target14.28 (1090%)
Short Float %0.58%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.55%
Min EPS beat(2)13.15%
Max EPS beat(2)25.94%
EPS beat(4)3
Avg EPS beat(4)-4.14%
Min EPS beat(4)-83.16%
Max EPS beat(4)27.52%
EPS beat(8)5
Avg EPS beat(8)-6.04%
EPS beat(12)7
Avg EPS beat(12)-1.88%
EPS beat(16)9
Avg EPS beat(16)-1.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-2.92
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-2.59
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS0
BVpS1.97
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.82%
ROE -143.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.81%
ROA(5y)-63.82%
ROE(3y)-64.26%
ROE(5y)-70.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.15
Quick Ratio 7.15
Altman-Z -9.83
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
EPS Next Y30.72%
EPS Next 2Y31.8%
EPS Next 3Y21.9%
EPS Next 5Y13.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-272.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-272.44%
OCF growth 3YN/A
OCF growth 5YN/A